The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem?
Article Abstract:
A 1992 law that speeded up the FDA drug approval process does not appear to be responsible for several unsafe drugs that had to be removed from the market. Between Sept, 1997, and Sept, 1998, fenfluramine, dexfenfluramine, terfenadine, mibefradil and bromfenac sodium were removed from the market because of reports of adverse effects. However, several of the drugs had been approved before the law was passed. Although mibefradil was approved after only 15 months, approvals for dexfenfluramine and bromfenac took 35 and 28 months, respectively. These two drugs were approved before the 1992 law. Postmarketing surveillance will be important in identifying dangerous drugs.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Recent advances and future frontiers in treating age-related cataracts
Article Abstract:
The surgical treatments for cataract are reviewed. A cataract occurs when the natural lens inside the eye becomes cloudy. This prevents light from passing through the lens and entering the eye. Most patients have the natural lens removed and replaced with an artificial intraocular lens.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Cost-benefit issues in the practice of internal medicine. The role of medical necessity and cost-effectiveness in making medical decisions
- Abstracts: Whole-abdominal irradiation for the management of gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia
- Abstracts: Variations in methadone treatment practices: results from a national study. Multiple risk factor intervention trial: risk factor changes and mortality results
- Abstracts: Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma
- Abstracts: To end an epidemic: lessons from the history of diphtheria. Idiopathic focal segmental glomerulosclerosis: new lessons from kidney transplantation